New triple therapy trial targets Tough-to-Treat kidney cancers
Disease control
Ongoing
This study is testing whether combining three medications—cabozantinib, nivolumab, and ipilimumab—can safely slow the growth of advanced kidney cancer that has spread. The trial will enroll about 60 adults with specific types of non-clear cell kidney cancer that cannot be surgica…
Phase: PHASE2 • Sponsor: Bradley A. McGregor, MD • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC